Applications of transrectal ultrasound in prostate cancer

British Journal of Radiology

Volumn 85, Issue SPEC. ISSUE 1, 2012, Pages

  Harvey, C J ^a   Pilcher, J ^b   Richenberg, J ^c   Patel, U ^b   Frauscher, F ^d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTIBIOTIC AGENT; CIPROFLOXACIN; DUTASTERIDE; GENTAMICIN; LIDOCAINE; PROSTATE SPECIFIC ANTIGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SHU 508; SONOVUE;

ANESTHESIA COMPLICATION; ANTIANDROGEN THERAPY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFACT; B SCAN; BACTERIAL INFECTION; BENIGN TUMOR; BIOPSY NEEDLE; BIOPSY TECHNIQUE; BLADDER BLEEDING; CANCER STAGING; CAPILLARY DENSITY; COLOR ULTRASOUND FLOWMETRY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ENDOCARDITIS; EPIDIDYMITIS; ERECTILE DYSFUNCTION; FALSE POSITIVE RESULT; FEVER; GLEASON SCORE; GRAY SCALE ECHOGRAPHY; GROUPS BY AGE; HEMOSPERMIA; HOSPITALIZATION; HUMAN; IMAGE GUIDED BIOPSY; INFECTION; INJECTION SITE PAIN; LOCAL ANESTHESIA; MICROBUBBLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT POSITIONING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; RECTUM HEMORRHAGE; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR INVASION; TUMOR VASCULARIZATION; ULTRASOUND SCANNER; UNSPECIFIED SIDE EFFECT; URETHRAL BLEEDING; URINE INCONTINENCE; URINE RETENTION; UROSEPSIS; YOUNG MODULUS; ECHOGRAPHY; IMAGE ENHANCEMENT; MALE; METHODOLOGY; PROSTATE TUMOR; RECTUM;

HUMANS; IMAGE ENHANCEMENT; MALE; PROSTATIC NEOPLASMS; RECTUM; ULTRASONOGRAPHY;

EID: 84872839966     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/56357549     Document Type: Article

References (78)

1. Northern Ireland Cancer Registry. Cancer incidence and mortality. Belfast, UK: NICR; 2010.
2. Welsh Cancer Intelligence and Surveillance Unit. Cardiff, UK: WCISU; 2010.
3. ISD Online Information and Statistics Division, NHS Scotland. Edinburgh, UK: ISD Scotland; 2010.
4. Office for National Statistics. Registrations of cancer diagnosed in 2008, England. Series MB1 no. 39. London, UK: National Statistics; 2010.
5. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-44.
6. Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme information for primary care: PSA testing for asymptomatic men. Sheffield, UK: NHS Cancer Screening Programmes; 2008.
7. Prostate Cancer UK. Incidence statistics. London, UK: Prostate Cancer UK. [Cited 6 January 2008.] Available from: http://info.cancerresearchuk.org/ cancerstats/types/prostate/incidence/?a55441#source12
8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
9. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep 2004;5:166-72.
10. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011;107:882-91.
11. Djulbeqovic M, Beyth R, Neuberger M, Stoffs T, Vieweq J, Djulbeqovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;14:341.
12. Onur R, Littrup PJ, Pontes JE, Bianco FJ Jr. Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. J Urol 2004;172:512-14.
13. Patel U, Rickards D. Handbook of transrectal ultrasound and biopsy of the prostate. London, UK: Martin Dunitz; 2002.
14. Patel U. The prostate and seminal vesicles. In: Allan P, Baxter G, Weston M, eds. Clinical ultrasound. 3rd edn. Edinburgh, UK: Churchill-Livingstone; 2011. pp. 572-92.
15. Kravchick S, Peled R, Ben Dor D, Dorfman D, Kesari D, Cytron S. Comparison of different local anaesthesia techniques during TRUS-guided biopsies: a prospective pilot study. Urology 2005;65:109-13.
16. Trucchi A, De Nunzio C, Mariani S, Palleschi G, Miano L, Tubaro A. Local anesthesia reduces pain associated with transrectal prostatic biopsy. A prospective randomized study. Urol Int 2005;74:209-13.
17. Lee-Elliott CE, Dundas D, Patel U. Randomised trial of lidocaine vs lidocaine/bupivacaine periprostatic injection on longitudinal pain scores after prostate biopsy. J Urol 2004;171:247-50.
18. Turgut AT, Dogra VS. Transrectal prostate biopsies. In: Dogra V, Saad W, eds. Ultrasound guided procedures. New York, NY: Thieme; 2009. pp. 85-93.
19. Turgut AT, Olçücüoǧlu E, Koşar P, Geyik PO, Koşar U. Complications and limitations related to periprostatic local anaesthesia before TRUS-guided biopsy. J Clin Ultrasound 2008;36:67-71.
20. Seymour H, Perry MJ, Lee-Elliot C, Dundas D, Patel U. Pain after transrectal ultrasonography-guided prostate biopsy: the advantages of periprostatic local anaesthesia. BJU Int 2001;88:540-4.
21. Obek C, Onal B, Ozkan B, Onder AU, Yalcin V, Solok V. Is periprostatic local anesthesia for transrectal ultrasound guided prostate biopsy associated with increased infectious or hemorrhagic complications? A prospective randomized trial. J Urol 2002;168:558-61.
22. Webb NR, Woo HH. Antibiotic prophylaxis for prostate biopsy. BJU Int 2002;89:824-8.
23. Ghani KR, Dundas D, Patel U. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int 2004;94:1014-20.
24. Lee G, Attar K, Laniado M, Karim O. Trans-rectal ultrasound guided biopsy of the prostate: nationwide diversity in practice and training in the United Kingdom. Int Urol Nephrol 2007;39:185-8.
25. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. Arnhem, the Netherlands: European Association of Urology; 2012.
26. Sadeghi-Nejad H, Simmons M, Dakwar G, Dogra V. Controversies in transrectal ultrasonography and prostate biopsy. Ultrasound Q 2006;22:169-75.
27. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEERmedicare. J Urol 2011;186:1830-4.
28. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostatic specific antigen: prospective evaluation within the ProtecT study. BMJ 2012;344:d7894.
29. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al. Continuing or discontinuing aspirin before transrectal prostate biopsy: results of a prospective randomised trial. Urology 2007;70:501-5.
30. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-4.
31. NHS Cancer Screening Programmes. Undertaking a transrectal ultrasound guided biopsy of the prostate. PRCMP Guide no. 1. Sheffield, UK: NHS Cancer Screening Programmes; 2006.
32. Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. World J Urol 2007;25:11-17.
33. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006;175:1605-12.
34. Loch T. Urologic imaging for localised prostate cancer in 2007. World J Urol 2007;25:121-9.
35. Gosselaar C, Roobol M, Roemeling S, Wolters T, van Leenders G, Schroder F. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU Int 2008;101:685-90.
36. Toi A, Neill M, Lockwood G, Sweet J, Tammsalu L, Fleshner N. The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007;177:516-20.
37. Raja J, Ramachandran N, Munneke G, Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006;61:142-53.
38. Purohit R, Shinohara K, Meng M, Carroll PR. Imaging clinically localized prostate cancer. Urol Clin North Am 2003;30:279-93.
39. Turgut A, Dogra V. Prostatic cancer: evaluation using transrectal sonography. In: Hayat M, ed. Methods of cancer diagnosis, therapy and prognosis. New York, NY: Elsevier; 2008. pp. 499-520.
40. Halpern E, Strup S. Using gray scale and color and power Doppler sonography to detect prostatic cancer. AJR Am J Roentgenol 2000;174:623-7.
41. Turgut A, Olcucuoglu E, Kosar P, Geyik PO, Koşar U, Dogra V. Power Doppler ultrasonography of the feeding arteries of the prostate gland: a novel approach to the diagnosis of prostate cancer? J Ultrasound Med 2007;26: 875-83.
42. Pallwein L, Mitterberger M, Pelzer A, Bartsch G, Strasser H, Pinggera GM, et al. Ultrasound of the prostate cancer: recent advances. Eur Radiol 2008;18:707-15.
43. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993;24:220-6.
44. Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2005;12:596-607.
45. Wijkstra H, Wink M, de la Rosette J. Contrast specific imaging in the detection and localisation of prostate cancer. World J Urol 2004;22:346-50.
46. Leen E, Averkiou M, Arditi M, Burns P, Bokor D, Gauthier T, et al. Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials. Eur Radiol 2012;22:1442-50.
47. Harvey CJ, Pilcher J, Eckersley R, Blomley MJK, Cosgrove DO. Advances in ultrasound. Clin Radiol 2002;57:157-77.
48. Cosgrove DO, Eckersley RJ, Blomley M, Harvey CJ. Quantification of blood flow. Eur Radiol 2001;11:1338-44.
49. Eckersley RJ, Cosgrove DO, Blomley MJ, Hashimoto H. Functional imaging of tissue response to bolus injection of ultrasound contrast agent. Proceedings of the 1998 IEEE Ultrasonics Symposium; 5-8 October 1998; Sendai, Japan. New York, NY: IEEE.
50. Goossen TE, de la Rosette JJ, Hulsbergen-van de Kaa CA, van Leenders GJ, Wijkstra H. The value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer. Eur Urol 2003;43:124-31.
51. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-83.
52. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast enhanced US for detection. Radiology 2001;219:219-25.
53. Frauscher F, Klauser A, Halpern EJ. Advances in ultrasound for the detection of prostate cancer. Ultrasound Q 2002;18:135-42.
54. Frauscher F, Klauser A, Halpern EJ. Detection of prostate cancer with a microbubble contrast agent. Lancet 2001;357: 1849-50.
55. Frauscher F, Klauser A, Volgger H, Halpern EJ, Pallwein L, Steiner H, et al. Comparison of contrast-enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer. J Urol 2002;167:1648-52.
56. Harvey CJ, Sidhu P. Ultrasound contrast agents in genitourinary imaging. Ultrasound Clin 2010;5:489-506.
57. Halpern EJ, Frauscher F, Rosenberg M, Gomella LG. Directed biopsy during contrast enhanced sonography of the prostate. AJR Am J Roentgenol 2002;178:915-19.
58. Aigner F, Pallwein L, Mitterberger M, Pinggera GM, Mikuz G, Horninger W, et al. Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int 2009;103:458-63.
59. Mitterberger M, Pinggera GM, Horninger W, Bartsch G, Strasser H, Schäfer G, et al. Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol 2007;178:464-8.
60. Mitterberger M, Aigner F, Horninger W, Ulmer H, Cavuto S, Halpern EJ, et al. Comparative efficiency of contrastenhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol 2010;20:2791-6.
61. Sedelaar JP, Van Leenders GJ, Hulsbergen-Van De Kaa CA, van der Poel HG, van der Laak JA, Debruyne FM, et al. Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol 2001;40:285-93.
62. Unal D, Sedelaar JP, Aarnink RG, van Leenders GJ, Wijkstra H, Debruyne FM, et al. Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: the value of diagnostic predictors of prostate cancer. BJU Int 2000;86:58-64.
63. Mitterberger M, Pinggera G, Horninger W, Strasser H, Halpern E, Pallwein L, et al. Dutasteride prior to contrastenhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol 2008;53:112-17.
64. Eckersley RJ, Butler-Barnes J, Blomley MJ, Cosgrove DO. Quantification microbubble enhanced transrectal ultrasound (TRUS) as a tool for monitoring anti-androgen therapy in prostate carcinoma. Radiology 1998;209:310.
65. Smeenge M, Mischi M, Laguna Pes M, de la Rosette J, Wijkstra H. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol 2011;29:581-7.
66. Tardy I, Pochon S, Theraulaz M, Emmel P, Passantino L, Tranquart F, et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol 2010;45:573-8.
67. Wink M, Frauscher F, Cosgrove D, Chapelon JY, Palwein L, Mitterberger M, et al. Contrast-enhanced ultrasound and prostate cancer: a multicentre European research coordination project. Eur Urol 2008;54:982-92.
68. Piscaglia F, Nolsøe C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann Nielsen M, et al. The EFSUMB guidelines and recommendations on clinical practice of contrast enhanced ultrasound (CEUS): update 2011. Ultraschall Med 2012;33: 33-59.
69. Sano F, Terao H, Kawahara T, Miyoshi Y, Sasaki T, Noguchi K, et al. Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer. BJU Int 2010;107:1404-10.
70. Strazdina A, Krumina G, Sperga M. The value and limitations of contrast-enhanced ultrasound in the detection of prostate cancer. Anticancer Res 2011;31:1421-6.
71. Hoskins P. Principles of ultrasound elastography. Ultrasound 2012;20:8-15.
72. Pallwein L, Mitterberger M, Struve P, Horninger W, Aigner F, Bartsch B, et al. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol 2007;17:2278-85.
73. Aigner F, Pallwein L, Junker D, Schafer G, Mikuz G, Pedross F, et al. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostatic specific antigen 1.25 or greater and 4 ng/ml or less. J Urol 2010;184:913-17.
74. Aigner F, Pallwein L, Schocke M, Lebovici A, Junker D, Schafer G, et al. Comparison of real-time sonoelastography with T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. J Ultrasound Med 2011;30:643-9.
75. Ukimura O, Gill IS. Image-fusion, augmented reality, and predictive surgical navigation. Urol Clin North Am 2009;36:115-23.
76. Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011;186:1281-5.
77. Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 2008;13:255.
78. Hadaschik B, Kuru T, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011;186:2214-20.